Stock SGHT SIGHT SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
6.56 USD +0.61% Intraday chart for Sight Sciences, Inc. +17.77% +27.13%
May. 28 Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis MT
May. 28 Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Sight Sciences Announces Publication of a New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI across Mild, Moderate, and Advanced Glaucoma
AQ
Sight Sciences Trial Results Show Improved Dry Eye Disease Signs, Symptoms for TearCare Patients Crossed Over From Restasis
MT
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis
AQ
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
AQ
Sight Sciences, Inc. Announces Publication of New Analysis from the ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with Omni®? Across Mild, Moderate, and Advanced Glaucoma
CI
Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
AQ
Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed
MT
Earnings Flash (SGHT) SIGHT SCIENCES Reports Q1 Revenue $19.3M, vs. Street Est of $18.4M
MT
Transcript : Sight Sciences, Inc., Q1 2024 Earnings Call, May 02, 2024
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
AQ
Sight Sciences, Inc. Provides Revenue Guidance for the Second Half of 2024 and Re-Affirms Earnings Guidance for the Full Year 2024
CI
Sight Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Sector Update: Health Care Stocks Edge Higher Late Afternoon
MT
Sector Update: Health Care Stocks Rise in Monday Afternoon Trading
MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
MT
Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
MT
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
AQ
Sight Sciences : SGHT Proxy - Apr'24
PU
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGHT Stock
  4. News Sight Sciences, Inc.